PandaOmics
AI-powered platform for therapeutic target and biomarker discovery and prioritization.
Executive Summary
PandaOmics is an advanced AI-powered platform developed by Insilico Medicine, launched in 2020, specifically designed for therapeutic target and biomarker discovery and prioritization. It leverages generative AI and integrates over 20 AI and bioinformatics models to provide actionable and explainable insights. The platform excels at scanning vast scientific literature to identify and extract relationships between genes, diseases, and other critical biological entities. This capability enables users to discover novel targets, prioritize diseases, and repurpose drugs more efficiently. Recent updates, such as PandaOmics 4.0, have introduced revolutionary approaches to generating Gene-Disease reports, crucial for in-depth drug target investigation. Designed to streamline drug discovery and development, PandaOmics can be integrated with other Insilico Medicine tools like Chemistry42, forming a comprehensive, end-to-end generative AI software and automation platform for pharmaceutical research.
Use Cases
- Discovering novel therapeutic targets
- Prioritizing diseases for drug development
- Identifying and prioritizing biomarkers
- Repurposing existing drugs for new indications
- Generating comprehensive Gene-Disease reports for drug target investigation
- Streamlining drug discovery workflows when combined with other Insilico tools
Features
Intelligence
- Explainable AI: Provides actionable and explainable insights into AI predictions for target discovery and prioritization.
- Literature Scanning: AI scans scientific literature to extract relationships between genes, diseases, and other relevant entities.
- Custom Analysis Methods: Allows users to build and customize analysis methods using PandaOmics data for dynamic insights.
Technical Specifications
- Deployment
- SaaS
- API Available
- Yes
AI/ML Stack
- Generative AI
- Bioinformatics AI
Integrations
- Chemistry42
About Insilico Medicine
Insilico Medicine is a clinical-stage biotechnology company that leverages artificial intelligence and deep learning to accelerate drug discovery and development. The company focuses on therapeutic solutions for cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions, utilizing its proprietary Pharma.AI platform to discover novel targets, design new molecules, and advance candidates into human clinical trials.